الولايات المتحدة · منصات وبيانات · Stocktwits

CAPR Stock Rallies: Investors Scrutinize Labeling Hints Before FDA Decision On Cell Therapy This Month

نشره Stocktwits · الولايات المتحدة منذ 8 س

ملخص مفصل

The U.S. Food and Drug Administration is slated to decide on approving Capricor’s Deramiocel for the treatment of Duchenne muscular dystrophy by November 22.

اقرأ المقال كاملًا على Stocktwits سجّل الدخول للحفظ

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (stocktwits.com)

يستحق القراءة أيضًا

MarketBeat

Fed's Goolsbee calls inflation report 'borderline disturbing' as central bank weighs more hikes

Benzinga

CAPR Stock Rallies: Investors Scrutinize Labeling Hints Before FDA Decision On Cell Therapy This Month

ملخص مفصل

مشاركة

يستحق القراءة أيضًا

Rumble (NASDAQ:RUM) Shares Up 11.8% - Here's Why

GAMCO Natural Resources Gold & Income Trust declares $0.06 dividend

Need money for a down payment? More employers are offering to help.

Chime at KBW fintech ecosystem conference: growth and margins rise

Fed's Goolsbee calls inflation report 'borderline disturbing' as central bank weighs more hikes

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030